aTyr Pharma, Inc. (ATYR) stock forecast & analysis
0.3044
NasdaqCM · USD
Down: -0.0332, -9.8%
1 analysis
- Open
- 0.3093
- Previous close
- 0.3376
- Day range
- 0.3032 – 0.3160
- 52-week range
- 0.3032 – 1.12
- Volume (shares)
- 2.76M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 98.09M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.53
- Market cap
- 29.86M
Market Scanner’s AI analysis of aTyr Pharma, Inc. (ATYR), updated September 2026: aTyr Pharma's efzofitimod Phase 3 protocol alignment with FDA contrasted with significant technical downtrend and declining financials.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of aTyr Pharma, Inc. (ATYR) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
aTyr Pharma's efzofitimod Phase 3 protocol alignment with FDA contrasted with significant technical downtrend and declining financials.
Recent analyses for aTyr Pharma (ATYR) covered the company's announcement of FDA alignment on the Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis. The reports also detailed a significant technical downtrend, with multiple indicators suggesting bearish momentum and oversold conditions. Fundamental data indicated declining annual revenue and widening net losses.
ATYR news & sentiment
News reports highlighted positive regulatory developments for aTyr Pharma regarding its Phase 3 study protocol. Social media discussion was not covered in the provided notes.
ATYR technical picture
Technical indicators showed ATYR in oversold territory, with the Relative Strength Index and Money Flow Index at extremely low levels. Short-term momentum readings were negative, while longer-term moving averages remained significantly above the current price, indicating a strong downtrend. The price was trading below the lower Bollinger Band, further reinforcing the oversold condition.
Fundamentals
Annual revenue has been declining, with net losses widening. The company reported negative gross profit and a highly negative return on equity.
Factors discussed — upside
- FDA alignment on Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis.
Factors discussed — risks
- Relative Strength Index (RSI) indicating oversold territory.
- 10-day EMA below last close, suggesting short-term downward momentum.
- 50-day and 200-day SMAs significantly above last close, indicating a long-term downtrend.
- MACD below zero and trending downwards, confirming bearish momentum.
- Price trading below the lower Bollinger Band, reinforcing oversold condition.
- Regulatory developments
- Technical indicators
- Financial performance
- Oversold conditions
Summary updated .
ATYR technical indicators
Common technical indicators for ATYR, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.48 | Price below |
| 10-day exponential moving average | 0.37 | Price below |
| Relative strength index (14-day) | 24.82 | Oversold |
| MACD line (12/26/9) | -0.0470 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.29 – 0.56 | Price inside the bands |
Analyses
Recent ATYR.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for aTyr Pharma, Inc.?
- The company announced alignment with the FDA on the protocol for its Phase 3 study of efzofitimod in pulmonary sarcoidosis, representing a significant step forward for its rare lung disease treatment.
- What are the risks for aTyr Pharma, Inc.?
- The company's stock is exhibiting significant technical downtrend signals, with multiple indicators pointing to short-term downward momentum and oversold conditions. Fundamental data indicates declining annual revenue and widening net losses over recent periods.
- Is aTyr Pharma, Inc. bullish or bearish?
- Recent AI analyses of aTyr Pharma, Inc. examined factors on both sides. Discussed upside: The company announced alignment with the FDA on the protocol for its Phase 3 study of efzofitimod in pulmonary sarcoidosis, representing a significant step forward for its rare lung disease treatment. Discussed risks: The company's stock is exhibiting significant technical downtrend signals, with multiple indicators pointing to short-term downward momentum and oversold conditions. Fundamental data indicates declining annual revenue and widening net losses over recent periods. These are descriptive observations, not a recommendation.
- What is the latest sentiment on aTyr Pharma, Inc.?
- News reports highlighted positive regulatory developments for aTyr Pharma regarding its Phase 3 study protocol. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse aTyr Pharma, Inc.?
- Every analysis of aTyr Pharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh ATYR.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.